Sage Journals: Discover world-class research

Retricted access

Review article

First published 2023-3

An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC)

Vanessa Quang Nguyen, Marc Geirnaert

Journal of Oncology Pharmacy Practice

Open access

Review article

First published 2023

Precision oncology with selective RET inhibitor selpercatinib in RET -rearranged cancers

Mohamed A. Gouda, Vivek Subbiah

Therapeutic Advances in Medical Oncology

Retricted access

Case report

First published 2025-12

Selpercatinib plus cemiplimab in RET positive medullary thyroid cancer patient with skin cancers

Laura Deborah Locati, Federica Puce, Vito Amoroso [...]

Tumori Journal

Retricted access

Research article

First published 2023-03-16

A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion

Ayanthi Wijewardene, Karine Bastard, Bin Wang [...]

VideoEndocrinology™

Retricted access

Case report

First published 2026

Central nervous system effectiveness of selpercatinib retreatment in heavily pretreated NSCLC patient with RET rearrangement: A case report

Margherita Agostini, Samuele Compagno, Francesca Sperandi [...]

Tumori Journal

Open access

Research article

First published 2022

Efficacy and safety of selpercatinib in Chinese patients with advanced RET -altered thyroid cancers: results from the phase II LIBRETTO-321 study

Xiangqian Zheng, Qinghai Ji, Yuping Sun [...]

Therapeutic Advances in Medical Oncology

Retricted access

Research article

First published 2022-06-28

Response to Selpercatinib in an Adolescent with RET Fusion-Positive Papillary Thyroid Carcinoma with Extensive Intracranial and Pulmonary Metastases

Priya Mahajan, Rajkumar Venkatramani

VideoEndocrinology™

Open access

Research article

First published 2021

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

Oliver Illini, Maximilian Johannes Hochmair, Hannah Fabikan [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2023

Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer,and RET -mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial

Shun Lu, Xiangqian Zheng, Yuping Sun [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2022

Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)

Shun Lu, Ying Cheng, Dingzhi Huang [...]

Therapeutic Advances in Medical Oncology

Search results